PURPOSE: To report the incidence of HPV-related oropharyngeal cancer (OC) in our region, and determine the influence of HPV status on survival among patients treated with chemoradiation (CRT). METHODS: A total of 102 patients with stage II-IV OC treated by CRT at four hospitals in Madrid, Spain were retrospectively reviewed. Immunohistochemistry analysis was performed to evaluate p16 expression in pretreatment tumor block samples obtained from these patients. HPV-positive and HPV-negative patients were compared to assess differences in overall survival (OS), loco-regional control and disease-free survival. RESULTS: Of the tumor samples evaluated, 26.7 % were p16 positive. HPV-positive patients were younger (median age, 56 vs 59 years; p = 0.052). No significant differences were observed in terms of tumor stage, gender, or smoking habit between HPV+ and HPV- patients. HPV+ patients showed a trend towards better OS (67.4, vs 49.7 %; hazard ratio, 0.55; p = 0.095). CONCLUSIONS: Incidence of HPV-related OC in our region is similar to that reported in other regions in Europe, yet lower than in North America. We observed a trend for improved OS in patients with HPV+ oropharyngeal cancer.
PURPOSE: To report the incidence of HPV-related oropharyngeal cancer (OC) in our region, and determine the influence of HPV status on survival among patients treated with chemoradiation (CRT). METHODS: A total of 102 patients with stage II-IV OC treated by CRT at four hospitals in Madrid, Spain were retrospectively reviewed. Immunohistochemistry analysis was performed to evaluate p16 expression in pretreatment tumor block samples obtained from these patients. HPV-positive and HPV-negative patients were compared to assess differences in overall survival (OS), loco-regional control and disease-free survival. RESULTS: Of the tumor samples evaluated, 26.7 % were p16 positive. HPV-positive patients were younger (median age, 56 vs 59 years; p = 0.052). No significant differences were observed in terms of tumor stage, gender, or smoking habit between HPV+ and HPV- patients. HPV+ patients showed a trend towards better OS (67.4, vs 49.7 %; hazard ratio, 0.55; p = 0.095). CONCLUSIONS: Incidence of HPV-related OC in our region is similar to that reported in other regions in Europe, yet lower than in North America. We observed a trend for improved OS in patients with HPV+ oropharyngeal cancer.
Authors: Andrew G Schache; Triantafilos Liloglou; Janet M Risk; Anastasia Filia; Terence M Jones; Jon Sheard; Julia A Woolgar; Timothy R Helliwell; Asterios Triantafyllou; Max Robinson; Philip Sloan; Colin Harvey-Woodworth; Daniel Sisson; Richard J Shaw Journal: Clin Cancer Res Date: 2011-10-01 Impact factor: 12.531
Authors: Shinta Tan; Brigitte M T Hougardy; Gert J Meersma; Bessel Schaap; Elisabeth G E de Vries; Ate G J van der Zee; Steven de Jong Journal: Mol Pharmacol Date: 2012-02-10 Impact factor: 4.436
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: Jordi Rubió-Casadevall; Elna Ciurana; Montserrat Puigdemont; Arantza Sanvisens; Jordi Marruecos; Josefina Miró; Antoni Urban; Rosa-Lisset Palhua; Ferran Martín-Romero; Maria Rosa Ortiz-Duran; Rafael Marcos-Gragera Journal: Int J Environ Res Public Health Date: 2022-04-15 Impact factor: 4.614
Authors: M Mena; J Frias-Gomez; M Taberna; B Quirós; S Marquez; O Clavero; A Baena; B Lloveras; M Alejo; X León; J García; R Mesía; O Bermejo; T Bonfill; A Aguila; M Guix; R Hijano; M A Pavón; M Torres; S Tous; R Clèries; L Alemany Journal: Sci Rep Date: 2020-08-06 Impact factor: 4.379